<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="27694">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02746185</url>
  </required_header>
  <id_info>
    <org_study_id>P141204</org_study_id>
    <nct_id>NCT02746185</nct_id>
  </id_info>
  <brief_title>Cancer Associated Thrombosis, a Pilot Treatment Study Using Rivaroxaban</brief_title>
  <acronym>CASTA-DIVA</acronym>
  <official_title>Efficacy and Safety of Oral Rivaroxaban for the Treatment of Venous Thromboembolism in Patients With Active Cancer. A Pilot Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will compare the efficacy and safety of oral rivaroxaban and subcutaneous
      dalteparin in patients with cancer associated thrombosis. It is designed as a
      non-inferiority open label randomized multicenter trial with blinded adjudication of outcome
      events.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with active cancer and symptomatic pulmonary embolism, proximal deep vein
      thrombosis, iliac or caval thrombosis will be randomly assigned to receive either dalteparin
      using the CLOT regimen or to oral rivaroxaban using the conventional dosage given in the
      Einstein studies. Experimental and control treatments will be given for three months. The
      main outcome at three month will include all symptomatic and incidentally discovered venous
      thromboembolic events including pulmonary embolism (either objectively confirmed and death
      due to pulmonary embolism), lower limb and upper limb deep vein thrombosis, iliac, caval and
      visceral thrombosis and any worsening of vascular obstruction which will be collected
      systematically at inclusion and at day 90. The safety end-points will consist of the rate of
      major bleedings and the composite of major and non-major but clinically significant
      bleedings at day 90. All outcome events will be blindly adjudicated by a central independent
      adjudication committee.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2016</start_date>
  <completion_date type="Anticipated">May 2017</completion_date>
  <primary_completion_date type="Anticipated">May 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single Blind (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Symptomatic DVT</measure>
    <time_frame>3 months</time_frame>
    <description>Recurrent VTE during the 3-month treatment period including all symptomatic DVT (lower limbs distal and proximal DVTs, iliac and caval thrombosis, visceral thrombosis and deep vein thrombosis of the arm)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Symptomatic PE</measure>
    <time_frame>3 months</time_frame>
    <description>Recurrent VTE during the 3-month treatment period including symptomatic PE</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Unsuspected PE and DVT</measure>
    <time_frame>3 months</time_frame>
    <description>Recurrent VTE during the 3-month treatment period including clinically unsuspected PE and DVT discovered incidentally</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Worsening of pulmonary vascular or venous obstruction</measure>
    <time_frame>3 months</time_frame>
    <description>Recurrent VTE during the 3-month treatment period including worsening of pulmonary vascular obstruction or venous obstruction on the systematic examinations performed at the end of the 3-month treatment period</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Major and clinically significant bleedings during the 3-month treatment period</measure>
    <time_frame>3 months</time_frame>
    <description>Major bleeding is defined according to the International Society on Thrombosis and Haemostasis (ISTH) criteria and includes any bleeding resulting in death; symptomatic bleeding in a critical organ including intracranial, intra spinal, intraocular, retroperitoneal, intra articular and pericardial bleeding and muscle bleeding resulting in compartment syndrome; symptomatic bleeding resulting in a decrease in the hemoglobin concentration of at least 2g/dL or resulting in the transfusion of at least two packs of blood red cells.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Symptomatic recurrences of PE or DVT of the legs</measure>
    <time_frame>3 months</time_frame>
    <description>excluding visceral thrombosis, upper extremity deep vein thrombosis and clinically unsuspected PE and DVT diagnosed incidentally</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major and non-major clinically significant bleedings at day 90</measure>
    <time_frame>3 months</time_frame>
    <description>Clinically significant non-major bleedings are defined as any bleeding requiring hospitalization or a medical intervention including temporary withholding of anticoagulant treatment to stop bleeding.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Rivaroxaban plasma concentrations</measure>
    <time_frame>3 months</time_frame>
    <description>Area under the plasma concentration versus time curve (AUC) determined using a liquid chromatography-tandem mass spectrometry method</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Neoplasm</condition>
  <condition>Venous Thromboembolism</condition>
  <arm_group>
    <arm_group_label>Low-molecular-weight heparin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>dalteparin, 200 IU/kg subcutaneously once daily for one month followed by 150 IU/kg subcutaneously once daily for 2 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Rivaroxaban</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>rivaroxaban, orally, 15 mg twice daily for 3 weeks followed by 20 mg once daily for 9 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rivaroxaban</intervention_name>
    <description>rivaroxaban, 15 mg BD (Bis in die) for 3 weeks followed by 20mg OD (Omni die) for 9 weeks</description>
    <arm_group_label>Rivaroxaban</arm_group_label>
    <other_name>xarelto</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Low-molecular-weight heparin</intervention_name>
    <description>dalteparin, 200 IU/kg OD for 4 weeks followed by 150 IU/kg OD for 8 weeks</description>
    <arm_group_label>Low-molecular-weight heparin</arm_group_label>
    <other_name>dalteparin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt; 18 years

          -  Social security affiliation

          -  Written informed consent

          -  Solid active cancer or myeloma treated with Immunomodulatory drugs (IMiDs)
             (thalidomide or lenalidomide). Active cancer is defined as the presence of measurable
             disease or ongoing (or planned) chemotherapy, radiotherapy or targeted therapy at
             inclusion.

          -  Histologically or cytologically proven cancer.

          -  Symptomatic venous thromboembolism objectively confirmed diagnosed because of
             symptoms or discovered incidentally

          -  High-risk of recurrent Venous thromboembolism (VTE) defined by a score ≥ 1, using the
             following criteria: female sex (+1), lung cancer (+1), breast cancer (-1) tumor stage
             1 (-2), previous VTE (+1).

        Exclusion Criteria:

          -  Exclusive adjuvant hormonal treatment with no measurable residual disease

          -  Sub-segmental isolated pulmonary embolism (PE) without associated proximal DVT

          -  Isolated distal deep vein thrombosis (DVT) of the legs

          -  Isolated upper-extremity DVT or superior vena cava thrombosis

          -  Isolated visceral thrombosis

          -  Platelet count &lt; 50 000 G/L

          -  Active bleeding

          -  Hepatic disease associated with coagulopathy and clinically relevant bleeding risk
             including cirrhotic patients with Child Pugh B and C

          -  Hemostatic defect with contraindication to anticoagulant treatment at therapeutic
             dosage

          -  Vena cava filter at inclusion

          -  Fibrinolytic therapy within 3 days preceding inclusion

          -  Creatinine clearance &lt; 30 ml/min according to Cockcroft-Gault formula

          -  Previous heparin-induced thrombocytopenia

          -  Anticoagulant treatment at curative dosage for more than 3 days before inclusion

          -  Pregnancy or lack of effective contraceptive treatment for women of childbearing age

          -  Contraindication to the use of contrast medium

          -  Treatment with both strong CYP3A4 and P-glycoprotein (PgP) inhibitors: protease
             inhibitors for HIV disease, systemic ketoconazole

          -  Treatment with a strong CYP3A4 inducer: rifampicin, carbamazepine, phenytoin.

          -  Life expectancy &lt; 3 months

          -  Eastern Cooperative Oncology Group (ECOG) level 3 or 4
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Guy Meyer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>APHP - HEGP</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Guy Meyer, MD</last_name>
    <email>guy.meyer@aphp.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Christine Lanau</last_name>
    <email>christine.lanau@aphp.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CHU Amiens - Medecine vasculaire (003)</name>
      <address>
        <city>Amiens</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marie-Antoinette SEVESTRE</last_name>
      <email>sevestre.marie-antoinette@chu-amiens.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Angers - Medecin Interne (002)</name>
      <address>
        <city>Angers</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Pierre Marie ROY</last_name>
      <email>pmroy@chu-angers.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hopital Saint Andre - Medecine vasculaire (015)</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joël CONSTANS</last_name>
      <email>joel.constans@chu-bordeaux.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Brest - Departement de medecin interne et pneumologie (008)</name>
      <address>
        <city>Brest</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aurelien DELLUC</last_name>
      <email>aurelien.delluc@chu-brest.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Le Bocage - Medecine interne 1 (014)</name>
      <address>
        <city>Dijon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Nicolas FALVO</last_name>
      <email>nicolas.falvo@chu-dijon.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Grenoble - Medecine vasculaire (007)</name>
      <address>
        <city>Grenoble</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Gilles PERNOD</last_name>
      <email>gpernod@chu-grenoble.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Bicetre - Service de Pneumologie et de soins intensifs (018)</name>
      <address>
        <city>Le Kremlin Bicetre</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Florence PARENT</last_name>
      <email>florence.parent@aphp.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre hospitalier Lyon Sud - Medecine interne (011)</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Claire GRANGE</last_name>
      <email>claire.grange@chu-lyon.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hopital Saint Eloi - Service de medecine Interne et Maladies Vasculaire (004)</name>
      <address>
        <city>Montpellier</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Isabelle QUERE</last_name>
      <email>i-quere@chu-montpellier.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHRU de Nîmes - Pneumologie (012)</name>
      <address>
        <city>Nîmes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alain PROUST</last_name>
      <email>alain.proust@chu-nimes.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>HEGP - Pneumologie et soins intensifs (001)</name>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Guy MEYER</last_name>
      <email>guy.meyer@aphp.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cochin - Medecine interne (017)</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Claire LE JEUNNE</last_name>
      <email>claire.le-jeunne@cch.aphp.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Curie - Soins de support en Cancerologie (020)</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexis BRUNOD</last_name>
      <email>alexis.burnod@curie.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre hospitalier de Pau - Service de Pneumologie (016)</name>
      <address>
        <city>Pau</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Gisele MOURIN</last_name>
      <email>gisele.mourin@chu-pau.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Saint Etienne - Medecin vasculaire et therapeutique (006)</name>
      <address>
        <city>Saint Etienne</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laurent BERTOLETTI</last_name>
      <email>laurent.bertoletti@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hopital Saine Musse - Service de Medecine Vasculaire (010)</name>
      <address>
        <city>Toulon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antoine ELIAS</last_name>
      <email>antoine.elias@free.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Rangueil - Medecin Vasculaire (019)</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Alessandra BURA</last_name>
      <email>bura-riviere@chu-toulouse.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <lastchanged_date>January 16, 2017</lastchanged_date>
  <firstreceived_date>December 15, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>cancer</keyword>
  <keyword>venous thromboembolism</keyword>
  <keyword>low-molecular weight heparin</keyword>
  <keyword>rivaroxaban</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Thromboembolism</mesh_term>
    <mesh_term>Venous Thromboembolism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Calcium heparin</mesh_term>
    <mesh_term>Heparin, Low-Molecular-Weight</mesh_term>
    <mesh_term>Dalteparin</mesh_term>
    <mesh_term>Rivaroxaban</mesh_term>
    <mesh_term>Heparin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
